炎症性肠病生物药物使用的全球患病率:系统回顾和荟萃分析。

IF 1.7 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY
Caroline Tianeze de Castro, Douglas da Silva Oliveira, Fabrício Freire de Melo, Mauricio Lima Barreto, Carlos Antonio de Souza Teles Santos, Djanilson Barbosa Dos Santos
{"title":"炎症性肠病生物药物使用的全球患病率:系统回顾和荟萃分析。","authors":"Caroline Tianeze de Castro, Douglas da Silva Oliveira, Fabrício Freire de Melo, Mauricio Lima Barreto, Carlos Antonio de Souza Teles Santos, Djanilson Barbosa Dos Santos","doi":"10.1080/00365521.2025.2491013","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Biologics are increasingly essential in managing inflammatory bowel diseases (IBDs) worldwide, as they can modify disease progression and improve patients' quality of life. This study aimed to analyze the global prevalence of and geographic variations in the use of biological drugs for IBD.</p><p><strong>Materials and methods: </strong>Articles published up to 21 July 2024, were identified from the PubMed/MEDLINE, Web of Science, Scopus, Embase, IBECS, WPRIM, BRISA/RedETSA and LILACS databases. Population-based studies (cohort, case-control and cross-sectional) and studies using administrative databases with data on the prevalence of biological medicine use in patients with IBD were included. Two reviewers independently screened the studies, extracted data, and assessed methodological quality. Estimates were pooled using a random-effects meta-analysis, whereas heterogeneity was evaluated using Cochran's <i>Q</i> test and <i>I</i><sup>2</sup>.</p><p><strong>Results: </strong>Of the 8239 titles, 68 (<i>n</i> = 3,482,385 patients) were included. An increase in the number of studies on the subject has been reported since 2017, and these studies have been mostly concentrated in high-income countries. A 15.06% (95% CI 11.84-18.28%) prevalence of biologic use in IBD worldwide was reported, predominantly concentrated in the use of anti-TNF agents 15.01% (95% CI 10.35-19.67%). Furthermore, patients with Crohn's disease (CD) had a greater prevalence of biologic use (21.41%; 95% CI 16.31-26.50%) than ulcerative colitis (UC) patients (9.70%; 95% CI 6.20-13.18%).</p><p><strong>Conclusions: </strong>Further studies using population-based and administrative data and stratifying their analyses by disease type are required to confirm our findings. Future studies should be conducted in Latin America, Asia and Africa.</p>","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":"60 5","pages":"439-453"},"PeriodicalIF":1.7000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Global prevalence of biologic drugs use in inflammatory bowel diseases: a systematic review and meta-analysis.\",\"authors\":\"Caroline Tianeze de Castro, Douglas da Silva Oliveira, Fabrício Freire de Melo, Mauricio Lima Barreto, Carlos Antonio de Souza Teles Santos, Djanilson Barbosa Dos Santos\",\"doi\":\"10.1080/00365521.2025.2491013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Biologics are increasingly essential in managing inflammatory bowel diseases (IBDs) worldwide, as they can modify disease progression and improve patients' quality of life. This study aimed to analyze the global prevalence of and geographic variations in the use of biological drugs for IBD.</p><p><strong>Materials and methods: </strong>Articles published up to 21 July 2024, were identified from the PubMed/MEDLINE, Web of Science, Scopus, Embase, IBECS, WPRIM, BRISA/RedETSA and LILACS databases. Population-based studies (cohort, case-control and cross-sectional) and studies using administrative databases with data on the prevalence of biological medicine use in patients with IBD were included. Two reviewers independently screened the studies, extracted data, and assessed methodological quality. Estimates were pooled using a random-effects meta-analysis, whereas heterogeneity was evaluated using Cochran's <i>Q</i> test and <i>I</i><sup>2</sup>.</p><p><strong>Results: </strong>Of the 8239 titles, 68 (<i>n</i> = 3,482,385 patients) were included. An increase in the number of studies on the subject has been reported since 2017, and these studies have been mostly concentrated in high-income countries. A 15.06% (95% CI 11.84-18.28%) prevalence of biologic use in IBD worldwide was reported, predominantly concentrated in the use of anti-TNF agents 15.01% (95% CI 10.35-19.67%). Furthermore, patients with Crohn's disease (CD) had a greater prevalence of biologic use (21.41%; 95% CI 16.31-26.50%) than ulcerative colitis (UC) patients (9.70%; 95% CI 6.20-13.18%).</p><p><strong>Conclusions: </strong>Further studies using population-based and administrative data and stratifying their analyses by disease type are required to confirm our findings. Future studies should be conducted in Latin America, Asia and Africa.</p>\",\"PeriodicalId\":21461,\"journal\":{\"name\":\"Scandinavian Journal of Gastroenterology\",\"volume\":\"60 5\",\"pages\":\"439-453\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Scandinavian Journal of Gastroenterology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/00365521.2025.2491013\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/16 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scandinavian Journal of Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/00365521.2025.2491013","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/16 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:生物制剂在全球范围内治疗炎症性肠病(IBDs)中越来越重要,因为它们可以改变疾病进展并改善患者的生活质量。本研究旨在分析IBD生物药物使用的全球患病率和地理差异。材料和方法:截止到2024年7月21日发表的文章,从PubMed/MEDLINE、Web of Science、Scopus、Embase、IBECS、WPRIM、BRISA/RedETSA和LILACS数据库中检索。纳入了基于人群的研究(队列研究、病例对照研究和横断面研究)和使用IBD患者生物药物使用流行率管理数据库的研究。两名审稿人独立筛选研究、提取数据并评估方法学质量。使用随机效应荟萃分析汇总估计,而使用Cochran's Q检验和I2评估异质性。结果:8239篇文献中,共纳入68篇(n = 3482385例)。自2017年以来,关于这一主题的研究报告数量有所增加,这些研究大多集中在高收入国家。据报道,世界范围内IBD生物制剂使用的患病率为15.06% (95% CI 11.84-18.28%),主要集中在抗tnf药物的使用15.01% (95% CI 10.35-19.67%)。此外,克罗恩病(CD)患者使用生物制剂的患病率更高(21.41%;95% CI 16.31-26.50%)高于溃疡性结肠炎(UC)患者(9.70%;95% ci 6.20-13.18%)。结论:需要使用基于人群和行政数据的进一步研究,并按疾病类型进行分层分析,以证实我们的发现。今后的研究应在拉丁美洲、亚洲和非洲进行。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Global prevalence of biologic drugs use in inflammatory bowel diseases: a systematic review and meta-analysis.

Objectives: Biologics are increasingly essential in managing inflammatory bowel diseases (IBDs) worldwide, as they can modify disease progression and improve patients' quality of life. This study aimed to analyze the global prevalence of and geographic variations in the use of biological drugs for IBD.

Materials and methods: Articles published up to 21 July 2024, were identified from the PubMed/MEDLINE, Web of Science, Scopus, Embase, IBECS, WPRIM, BRISA/RedETSA and LILACS databases. Population-based studies (cohort, case-control and cross-sectional) and studies using administrative databases with data on the prevalence of biological medicine use in patients with IBD were included. Two reviewers independently screened the studies, extracted data, and assessed methodological quality. Estimates were pooled using a random-effects meta-analysis, whereas heterogeneity was evaluated using Cochran's Q test and I2.

Results: Of the 8239 titles, 68 (n = 3,482,385 patients) were included. An increase in the number of studies on the subject has been reported since 2017, and these studies have been mostly concentrated in high-income countries. A 15.06% (95% CI 11.84-18.28%) prevalence of biologic use in IBD worldwide was reported, predominantly concentrated in the use of anti-TNF agents 15.01% (95% CI 10.35-19.67%). Furthermore, patients with Crohn's disease (CD) had a greater prevalence of biologic use (21.41%; 95% CI 16.31-26.50%) than ulcerative colitis (UC) patients (9.70%; 95% CI 6.20-13.18%).

Conclusions: Further studies using population-based and administrative data and stratifying their analyses by disease type are required to confirm our findings. Future studies should be conducted in Latin America, Asia and Africa.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.40
自引率
5.30%
发文量
222
审稿时长
3-8 weeks
期刊介绍: The Scandinavian Journal of Gastroenterology is one of the most important journals for international medical research in gastroenterology and hepatology with international contributors, Editorial Board, and distribution
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信